+ data and comment +, page-3

26 Oct: ARIDOL PHASE III ASTHMA TRIAL SUCCESSFUL

http://stocknessmonster.com/news-item?S=PXS&E=ASX&N=347045

Extract:
Pharmaxis (ASX:PXS) is pleased to announce the Phase III clinical trial of AridolTM achieved its endpoints. The trial was designed to evaluate Aridol as a test for asthma.

The positive results mean the company will apply for marketing authorisation later this year in Australia, and early in 2005 in Europe. Subject to regulatory approval, sales of Aridol are
expected to commence in 2005.

The annual revenue potential of Aridol as a management tool for Asthma is estimated to be in excess of $250 million".